| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Iterum Therapeutics (NASDAQ:ITRM) will release its quarterly earnings report on Friday, 2025-11-14. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Iterum Therapeutics to report an earnings per share (EPS) of $-0.11.
The market awaits Iterum Therapeutics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
During the last quarter, the company reported an EPS missed by $0.00, leading to a 0.66% increase in the share price on the subsequent day.
Here's a look at Iterum Therapeutics's past performance and the resulting price change:
| Quarter | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.13 | -0.14 | -0.24 | -0.21 |
| EPS Actual | -0.13 | -0.10 | -0.12 | -0.24 |
| Price Change % | 1.00 | 0.00 | -4.00 | 1.00 |
Shares of Iterum Therapeutics were trading at $0.5993 as of November 12. Over the last 52-week period, shares are down 56.2%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.
To track all earnings releases for Iterum Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ITRM
